Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 765316, 12 pages
Research Article

7 𝜶 -Hydroxy- 𝜷 -Sitosterol from Chisocheton tomentosus Induces Apoptosis via Dysregulation of Cellular Bax/Bcl-2 Ratio and Cell Cycle Arrest by Downregulating ERK1/2 Activation

1Genetics & Molecular Biology Division, Institute of Biological Science, Faculty of Science, University of Malaya, 50603 Kuala Lumpur, Malaysia
2Chemistry Department, Faculty of Science, University of Zakho, Zakho, Kurdistan Region, Iraq
3Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
4Centre for Natural Product Research and Drug Discovery (CENAR), Department of Chemistry, Faculty of Science, University of Malaya, 50603 Kuala Lumpur, Malaysia

Received 27 April 2012; Revised 26 July 2012; Accepted 26 July 2012

Academic Editor: Olumayokun A. Olajide

Copyright © 2012 Mohammad Tasyriq et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


In continuation of our interest towards the elucidation of apoptotic pathways of cytotoxic phytocompounds, we have embarked upon a study on the anticancer effects of 7α-hydroxy-β-sitosterol (CT1), a rare natural phytosterol oxide isolated from Chisocheton tomentosus. CT1 was found to be cytotoxic on three different human tumor cell lines with minimal effects on normal cell controls, where cell viability levels were maintained ≥80% upon treatment. Our results showed that cell death in MCF-7 breast tumor cells was achieved through the induction of apoptosis via downregulation of the ERK1/2 signaling pathway. CT1 was also found to increase proapoptotic Bax protein levels, while decreasing anti-apoptotic Bcl-2 protein levels, suggesting the involvement of the intrinsic pathway. Reduced levels of initiator procaspase-9 and executioner procaspase-3 were also observed following CT1 exposure, confirming the involvement of cytochrome c-mediated apoptosis via the mitochondrial pathway. These results demonstrated the cytotoxic and apoptotic ability of 7α-hydroxy-β-sitosterol and suggest its potential anti-cancer use particularly on breast adenocarcinoma cells.

1. Introduction

The tropical plant Chisocheton tomentosus from the Meliaceae family is a medium-sized tree that can grow upto 21 m in height [1]. Chisocheton species were known to produce bioactive compounds with complex molecular structures such as erythrocarpine E and chisomecine A [2, 3]. Plants from this family have been known to be a rich source of secondary metabolites including various sterols, terpenoids, and alkaloids, with medicinal and pesticidal properties such as antifungal, antibacterial, antiviral, anti-inflammatory, and antiplasmodial agents [46]. In tropical countries, this plant has been used as a form of traditional medicine against several diseases including diabetes, malaria, liver, and cancer diseases [79].

Plant-derived sterols or phytosterols are structurally similar to cholesterol with a slight difference at the C-24 position containing an additional ethyl group [10]. About 44 phytosterols have been identified to date, with major forms existing in higher plants constituted by β-sitosterol, campesterol, and stigmasterol [1114]. Past studies have also shown that β-sitosterol possesses a relatively large dipole moment, giving it a polar or hydrophilic nature which is a desirable trait in most in vivo drug applications [13]. β-sitosterols have also been reported to bind various carrier proteins such as human serum albumin mainly by hydrophobic and hydrogen bond interactions, thus making protein-drug combination complexes a viable option for chemotherapy [15].

Sitosterols often undergo oxidation processes to form sitosterol oxidation products (SOPs) [16]. These forms of sterols are structurally different from parent with an additional steroid ring group of either hydroxy- (OH–), keto (=O), epoxy, or triol [17]. Various forms of SOP that exist in human plasma are β-epoxysitostanol, sitostanetriol, campestanetriol, α-epoxysitostanol, 7-ketositosterol, and 7β-hydroxysitosterol, with β-epoxysitostanol, sitostanetriol, and campestanetriol being the most abundant SOPs [18].

In recent years, researchers have been focusing on the effects of phytosterols toward various cancer cell lines and their implication in multidrug resistance [1921]. To date, several apoptotic pathways mediated by phytosterols have been proposed in cancer culture models such as the Ras/ERK and the PI3 K/Akt pathway [2226]. In contrast, investigation on the mechanistic effects of phytosterol oxides is still scarce. Despite several reports on the cytotoxicity of these compounds, their cytotoxic mechanism of action is, however, still unclear [18, 27]. Roussi et al. [28] suggested that 7β-hydroxysitosterol, one of the many phytosterol oxides, could target the mitochondria, leading to loss of mitochondrial membrane potential to induce cytochrome c release. However, the mechanism of cytochrome c release and caspase activation was not well characterized [2830].

In this study, the cytotoxic effects of 7α-hydroxy-β-sitosterol (CT1) isolated from Chisocheton tomentosus (Meliaceae) was investigated on human breast, liver, and oral cancer cell lines, while its apoptotic potential and anticancer mechanism was elucidated on MCF-7 human breast cancer cell line for the first time.

2. Materials and Methods

2.1. Plant Material

Dried bark of Chisocheton tomentosus was collected from Mersing, Johor, Malaysia in 1993. The sample was identified by Mr. Teo from the Department of Chemistry, Faculty of Science, University of Malaya. A voucher specimen KL-4251 was deposited in the Department of Chemistry Herbarium, University of Malaya.

2.2. Reagents

Dulbecco’s modified Eagle’s medium (DMEM) and Roswell Park Memorial Institute-1640 (RPMI-1640) were purchased from Thermo Scientific (IL, USA). Trypsin and fetal bovine serum (FBS) were purchased from Sigma Aldrich (KS, USA). Mammary epithelial growth media (MEGM) and all antibiotics were purchased from Lonza Inc. (MD, USA). Dimethyl-2-thiazolyl-2,5-diphenyl-2H-tetrazolium bromide (MTT) reagent, annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit, propidium iodide (PI), RNase and SuicideTrack DNA ladder isolation kit were purchased from Calbiochem (CA, USA). Primary antibodies against caspase-9, caspase 3, caspase-6, caspase-8, XIAP, Bcl-2, Bax, Bim, Fas-L, p42/44, and β-actin were obtained from Cell Signaling (MA, USA).

2.3. Extraction and Isolation Compounds

Dried ground bark of Chisocheton tomentosus (3.5 kg) was first defatted with hexane for five days, followed by dichloromethane (DCM) for five days. DCM was removed through evaporation using a rotary evaporator. The crude extract (10.0 g) was subjected to a silica gel column (hexane : DCM, 95 : 5) and eluted gradiently using hexane : DCM and DCM : acetone to yield five fractions. The fifth fraction (DCM : acetone, 60 : 40) was further subjected to an isocratic separation using a silica gel column with (acetone : DCM : hexane, 25 : 25 : 50) to give five other fractions. The third fraction in the solvent was allowed to evaporate to yield colorless crystals of 7α-hydroxy-β-sitosterol or CT1 (0.2 g). Identification of CT1 was elucidated by comparison with known samples by their UV, IR, 1D-NMR, and 2D-NMR spectra and melting points [31]. A complete description of the entire extraction process and identified compounds is available under Supplementary Material  1 (see Supplementary Material available online at doi: 10.1155/2012/765316).

2.4. Cell Lines and Culture Conditions

A set of four human tumor cell lines were used in this study: Ca Ski cervical cancer cells and HepG2 liver cancer cells which was obtained from Professor Dr. Rohana, University of Malaya Medical Center (UMMC), HSC-4 oral cancer cells and MCF-7 breast adenocarcinoma cells were obtained from Dr. Eswary Thirthagiri, Cancer Research Initiative Foundation (CARIF, Malaysia), and HMEC human mammary epithelial cells purchased from Lonza Inc. (MD, USA) was used as a normal cell control. For routine maintenance, MCF-7 cells were cultured in RPMI-1640, while HSC-4, Ca Ski, and HepG2 cells were cultured in DMEM, with both media types supplemented with 10% (v/v) FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin. HMEC cells were cultured in serum-free mammary epithelial growth media (MEGM). Cells were grown as monolayers at 37°C in humidified atmosphere with 5% CO2 and 95% air.

2.5. MTT Cell Viability Assay

Cell viability was measured using the MTT assay method. Briefly, CT1 was dissolved in dimethyl sulfoxide (DMSO) to a final concentration of 10.0 mM. Cells were seeded at 1.0 × 104 cells/well in 96-well plates and treated with final CT1 concentrations from 0.5 to 80.0 μM for 24 h with DMSO as a solvent control. After treatment, 10.0 μL MTT (5.0 mg/mL) was added to each well and incubated at 37°C for 2 h. After incubation, the medium was replaced with 200.0 μL of DMSO and absorbance measured at 570 nm for each well using a microplate reader (Tecan Sunrise, Switzerland). Absorbance was compared against vehicle-treated control and expressed as mean percentage of viable cells.

2.6. Live/Dead Assay

Cytotoxic effects of four cell lines treated with CT1 were performed using LIVE/DEAD viability/cytotoxicity kit for mammalian cells (Invitrogen, NY, USA) according to manufacturer’s protocol. Briefly, cells were grown on cover slips and treated for 12 h. Staining was done using a 150.0 μL dual fluorescence staining system consisting of calcein acetoxymethyl ester (2.0 μM) and ethidium homodimer (4.0 μM). Excitation and emission wavelengths of both fluoresceins were set at 494/517 nm for calcein acetoxymethyl ester and 528/617 nm for ethidium homodimer, respectively. Samples images were capture using a Nikon Eclipse TS-100 fluorescence microscope (Nikon, Tokyo, Japan) under 100x magnification. All images were analyzed using the NIS Element D 3.1 data analysis software (Nikon, Tokyo, Japan).

2.7. Wound Healing Assay

Wound healing was used to examine the antimigration effects of CT1 on cancer cells. Briefly, cells were grown on 6-well plates for 24 h followed by treatment with mitomycin-c for 2 h. Media was removed and equal size wounds were created with a pipette tip. Cells were washed twice with 1x PBS and serum free media was added. Each group was incubated with media only, DMSO, or CT1 for 24 h. Images were captured using a Nikon Eclipse TS-100 fluorescence microscope (Nikon, Tokyo, Japan) under 100x magnification and analyzed using T-Scratch software v7.8 [32].

2.8. Cell Cycle Analysis

Both MCF-7 and HMEC cells were treated with CT1 for 12 h and 24 h before fixation. Briefly, 1.0 × 105cells was pelleted, rinsed with 1x PBS, and fixed with 70% (v/v) cold ethanol while mixing. Fixed samples were stored at −20°C overnight and stained with 1.0 mL of PBS containing 50.0 μg/mL PI and 0.1 mg/mL RNase A. Fluorescence from a population of 1.0 × 104 cells were detected using the FASCanto II (Becton Dickinson, CA, USA) and analyzed using the ModFit Lt 3.2 software (Tree Star Inc, OR, USA).

2.9. Annexin V-FITC/PI Analyses

Detection of apoptosis was conducted using the Annexin V-FITC/PI apoptosis detection kit according to manufacturer’s protocol. Briefly, both CT1-treated and untreated MCF-7 and HMEC cells were washed twice with 1x PBS and resuspended in binding buffer. Cell suspensions were stained with 1.25 μL of annexin V-FITC conjugate and 10.0 μL of PI. Detection of signals from 1.0 × 104 cells were obtained using the FASCanto II (Becton Dickinson, CA, USA) and analyzed using the FACS Diva acquisition and analysis software (Becton Dickinson, CA, USA).

2.10. DNA Fragmentation Assay

Detection of apoptotic fragmented DNA was performed using the Suicide-Track DNA isolation kit according to manufacturer’s protocol. After 24 h of incubation with CT1 cells were collected and total DNA was extracted from cells. Samples were loaded into a 1.5% (w/v) agarose gel and separated by electrophoresis. DNA fragments were stained with ethidium bromide and were visualized under UV illumination using the Alpha Imager Gel Documentation System 2000 (Inotech, CA, USA).

2.11. Western Blot

To determine pro- and antiapoptotic protein levels, CT1-treated MCF-7 total proteins were extracted using the NE-PER nuclear and cytoplasmic extraction kit (Pierce, IL, USA) according to manufacturer’s protocol. Protein concentrations were determined using the Bio-Rad DC protein assay (Bio Rad, CA, USA) according to manufacturer’s protocol. Equal amounts of protein were subjected to 12% to 15% (w/v) SDS-PAGE and transferred onto 0.2 μM nitrocellulose membranes using a Trans Blot Semidry blotter (Bio Rad, CA, USA). Membranes were blocked either with 2% (w/v) BSA or 2% (w/v) nonfat skim dry milk, and incubated with primary antibodies against β-actin, Bax, Bcl-2, Bim, caspase-6, caspase-3, caspase-9, caspase-8, XIAP, FasL, and ERK1/2. Horseradish peroxidase-(HRP-)linked secondary antibodies were added and bound proteins were detected through enhanced chemiluminescence reagent exposed on X-ray films. Relative intensities of bands were quantified using the ImageJ v1.43 analysis software (NIH, MD, USA).

2.12. Statistical Analysis

All results were expressed as mean ± SEM obtained from three independent experiments. Statistical significances between various groups were determined using one-way ANOVA with a 𝑃 value ≤0.05 threshold.

3. Results and Discussion

3.1. Characterization of 7α-Hydroxy-β-Sitosterol (CT1)

CT1 was isolated as a colorless crystal with the UV spectrum showing absorption at 𝜆 m a x 302 nm and 254 nm, IR spectrum showing the presence of hydroxyl group by the absorption band at 𝜈 m a x 3430 cm−1, and GCMS spectrum revealing a molecular ion peak [M]+ at m/z 430, corresponding to a molecular formula of C29H50O2. The 1H-NMR spectrum showed six methyl groups resonating as singlets, doublets, and triplets. Broadband decoupled 13C-NMR spectrum displayed twenty-nine carbon atoms in the molecule, the DEPT spectra exhibited six methyl, ten methylene, and ten methine carbons, while the remaining three carbons were quaternary as deduced from broadband spectrum. All protons of methyl, methylene, sp3 methine, and sp2 methine were approved by HMQC. HMBC spectrum showed long range correlation of C-19 proton with quaternary carbon of C-10, while C-18 methyl protons showed HMBC connectivity with quaternary C-13, indicating that the methyl group (19 and 18) was attached directly with C-10 and C-13, respectively, and the long chain substituent should be attached in the position of C-17 (Table 1). The signal C-5 ( 𝛿 c 146.3) of the compound was shifted toward the lower magnetic field (Figure 1(a)) [33]. Therefore, the configuration of hydroxyl group at C-7 was identified as an α form [3437]. Consequently, CT1 was identified as 7α-hydroxy-β-sitosterol. (Figure 1(b)).

Table 1: 1D (1H and 13C) and 2D (HMQC and HMBC) NMR spectral data of of 7 𝛼 -hydroxy- 𝛽 -sitosterol (CT1).
Figure 1: (a) Molecular structure of 7α-hydroxy-β-sitosterol (CT1). The ellipsoids denote 70% probability. Hydrogen atoms are drawn as spheres of arbitrary radii [33]. (b) Chemical structure of 7α-hydroxy- 𝛽 -sitosterol isolated from Chisocheton tomentosus bark.
3.2. CT1 Displayed Cytotoxic Effects on Various Cancer Cell Lines

MTT cell viability assay was used to evaluate the cytotoxic effects of CT1 on four human cancer and an HMEC normal cell line. Results indicated the induction of cytotoxicity in a dose- and time-dependent manner over 24 h of exposure. Minimal cytotoxic effects were observed on HMEC control cells, where 1 7 . 6 ± 4 . 2 % killing was observed under similar treatment conditions, as opposed to 7 8 . 7 ± 3 . 1 % in MCF-7 cells which indicated the lowest IC50 value of 1 6 . 0 ± 3 . 6 μM among all cell lines tested (Table 2). Viability of cells treated with DMSO (≤2.0% v/v) was insignificantly affected (data not shown), thereby ruling out the occurrence of solvent-induced cytotoxicity. Live/dead viability/cytotoxicity assays (Figures 2(a) and 2(b)) corresponded with MTT data, thereby supporting the need to further investigate the apoptotic effects of CT1 for the treatment of breast cancer. All subsequent experiments were carried out based on IC50 values as obtained from MTT experiments.

Table 2: Summary of IC50 values and total cell viability of CT1-treated tumor cell lines and HMEC cells as obtained from MTT cell viability assays after 24 h exposure. All data are presented as mean ± SEM after deduction of DMSO solvent-induced cytotoxicity of three independent experiments.
Figure 2: Live/dead viability/cytotoxicity assay depicting the cytotoxic effects of CT1 in tumor cell lines with minimal cytotoxic effects on HMEC normal cell controls. (a) Fluorescence microscope images of viable cells stained with acetomethoxy derivate of calcein (green) and nonviable cells stained with ethidium homodimer 1 (red). (b) Percentage of viable cells as calculated under a fluorescence microscope. A total of four random quadrants were selected from each triplicate for quantification. All data were presented as mean ± SEM.
3.3. CT1 Induces Apoptosis-Mediated Cell Death

We next determined whether CT1 cytotoxic effects were mediated through apoptosis or necrosis using DNA fragmentation assay and double fluorescence staining of annexin V-FITC/PI flow cytometry assay. An increase in cellular staining with FITC-conjugated annexin-V serves as an early marker for apoptosis while staining with PI indicates loss of cell membrane integrity. Treatment of MCF-7 cells was found to induce apoptotic cell death by observing a shift in viable cell population from early to late stage of apoptosis, followed by secondary necrosis. The percentage of MCF-7 viable cells decreased from 91.2% to 45.1%, while total percentage of apoptotic MCF-7 cells was 46.6% after 24 h (Figure 3(a)). Minimal apoptotic population shifts were observed in HMEC cells after similar treatments. DNA extracted from CT1-treated cells also showed DNA laddering with approximately 200 bp to 250 bp intervals as the result of endonuclease action at sites between nucleosomes, thus confirming the occurrence of apoptosis (Figure 3(b)).

Figure 3: CT1 potentiates apoptosis-mediated cell death in MCF-7 human breast cancer cells. (a) Detection of apoptosis using flow cytometry after annexin V-FITC/propidium iodide (PI) staining. MCF-7 cells and HMEC cells were treated with CT1 at IC50 concentrations for 24 h. Dot plots are a representative of 1.0 × 104 cells of three replicates with percentage of cells indicated in each quadrant. (b) Confirmation of apoptosis-mediated cell death through observation of a 200 to 250 bp DNA laddering using the DNA fragmentation assay. Cells were treated with CT1 for 24 h followed by analysis of extracted DNA on 1.0% (w/v) agarose gel electrophoresis. +ve: positive control. M: 100 bp DNA size marker.
3.4. Induction of Cell Cycle Arrest and Antimigration Effects of CT1

The effects of CT1 on cell cycle progression using flow cytometry PI-based staining showed an increase in the population of sub-G1 phase from 11.1% to 55.0% after 24 h incubation. The increase was consistent with a reduction in the G0/G1 phase from 70.8% to 35.0% after 24 h indicating a potential cell cycle arrest during the G0/G1 phase as there were minimal changes in both S and G2/M phases after 24 h of CT1 treatment (Figure 4). Cell cycle profiles for HMEC normal human breast cell controls were found to be consistent after 12 h and 24 h exposure. Wound healing assays also showed that HSC-4 cells treated with CT1 migrated at a slower rate compared to MCF-7 cells, indicating that CT1 was more effective in preventing cellular migration in oral cancer (Figure 5). Antimigration effects on HepG2 cells were found to be absent with treated cells showing comparable migration rates as untreated cells (data not shown).

Figure 4: Cell cycle distribution of MCF-7 and HMEC cells using flow cytometry after staining with PI for 12 h and 24 h. I: Sub-G1; II: G0/G1; III: S; IV: G2/M. All experiments were a representative of 1.0 × 104 cells and the percentage of cells in phases is indicated.
Figure 5: Wound healing assay displaying the antimigration effects of CT1 on HSC-4 cells, with minimal effects on MCF-7 cells. All cells were treated with mitomycin c to halt proliferation, followed by CT1 at IC50 concentrations for 12 h. Wound edge images of each independent triplicate were captured and measured at 24 h aftertreatment using T-scratch software, and percentage of migration is indicated as mean ± SEM.
3.5. CT1 Reduces ERK1/2, FasL, Bcl-2, and Bim Protein Levels

Western blot analysis of CT1-treated MCF-7 cells was carried out to observe the effects on ERK1/2, FasL, and Bcl-2 family of apoptotic proteins. Results showed that protein levels of both ERK1 and ERK2 declined over 24 h, while the level of the FasL increased dramatically by almost five-folds over 24 h compared to untreated cells (Figures 6(a) and 6(b)). Protein levels of the pro-apoptotic Bim and Bcl-2 also decreased after CT1 treatment and were completely absent 12 h aftertreatment, favoring the induction of apoptosis (Figures 6(a) and 6(b)). Furthermore, protein levels of pro-apoptotic Bax were found to be slightly elevated after 24 h, with consistent XIAP protein levels. Due to the dimerization nature of Bcl-2 family proteins, the ratio between Bax/Bcl-2 protein levels were measured and indicated a 9.7-fold increase at 12 h, which further increased to 26.6-folds higher compared to control cells at 24 h (Figures 6(a) and 6(b)).

Figure 6: Observation on the effects of CT1 treatment over 24 h on MCF-7 protein levels using Western blot. (a) CT1 was found to decrease ERK1/2 and anti-apoptotic Bcl-2 and Bim protein levels, while increasing FasL protein levels. XIAP and proapoptotic Bax protein levels were unaffected following CT1 exposure. β-actin was used as a normalization control for all experiments. (b) Quantification of protein band intensities were determined by densitometry analysis and normalized to β-actin using the ImageJ v1.43 software. All results were presented as mean normalized intensity ± SEM of three independent experiments.
3.6. CT1 Induces Intrinsic Caspase-Mediated Apoptosis in MCF-7 Cells

The involvement of FasL and Bcl-2 family members implied that induction of apoptosis by CT1 was mediated via both the mitochondrial and death receptor pathway. Therefore, we also assessed the protein levels of various procaspases through Western blot analysis. Our data demonstrated that CT1 induced the reduction of procaspase-3, -6, and -9 levels leading to an increase in active effector caspase forms (Figures 7(a) and 7(b)). Reduction in procaspase-8 protein levels was found to be transient over the first 6 h with protein levels starting to increase 12 h aftertreatment onwards, suggesting that the extrinsic death receptor pathway was used to augment the apoptotic signals arising from the intrinsic pathway.

Figure 7: Activation of caspases upon CT1 treatment in MCF-7 cells. (a) Western blot analysis on protein levels of various procaspases upon CT1 treatment. MCF-7 cells was treated with 16.0 μM of CT1 for 6 h, 12 h, and 24 h, respectively. Western blot of cell extracts were probed using the indicated procaspase antibodies and β-actin as a normalization control. (b) Normalization on band intensities between procaspases and β-actin was determined by densitometry using the ImageJ v1.43 software, and results were presented as a mean normalized intensity ± SEM of three independent experiments.

4. Discussion

To date, natural plant compounds have shown great potential as apoptosis-inducing agents in cancer cells [38]. Results from this study clearly indicated the potential benefits of phytosterol oxides, specifically 7α-hydroxy-β-sitosterol in the prevention of breast adenocarcinoma. Current cytotoxicity data have demonstrated that IC50 values of CT1 after 24 h of incubation on all cancer cell lines tested were within the range of 16.0 μM to 32.0 μM, which is comparable to most commercialized phytocompounds. It is suggested that variations in CT1 toxicity in different cancer types may be attributed to various reasons including cellular accessibility, genetic variability of cell lines, and circadian variations [39]. In terms of structure-activity relationship, we found that the presence of a 7α-OH on CT1 augmented its cytotoxicity towards HepG2 cancer cells when compared to 7β-OH sitosterols [40]. Sitosterol derivatives with an oxidized steroid ring were also found to be a more favorable trait compared to oxidized stigmasterol derivatives following reports on cytotoxicity levels in MCF7 and HepG2 cells [10, 41]. These observations highlighted the importance of 7α-OH phytosterols in governing in vitro biological activity and suggested the superiority of CT1 (7α-hydroxy-β-sitosterol) over other phytosterol counterparts.

One of the crucial factors which contribute towards proliferating breast cancer cells is the activation of the mitogen-activated protein kinase (MAPK/ERK) cascade, which can be prevented by using agents that prevent ERK1/2 activation [42]. Extracellular signal-regulated kinase (ERK1/2), which is expressed ubiquitously in mammalian cells, is multifunctional serine/threonine kinases that phosphorylate a vast array of substrates localized in all cellular compartments [43]. In normal cells, sustained activation of ERK1/2 promotes G1 to S phase progression and inhibits antiproliferative genes, while its hypoactivation by MEK inhibitors can induce cells to undergo cell cycle arrest [44]. Our current study showed that CT1 was able to inhibit cell cycle progression at the G0/G1 phase after 24 h, which corresponded to reduced protein levels of ERK1/2 as shown in our Western blot analysis.

Members of the Bcl-2 family have been identified as key regulators of apoptosis and are further divided into pro-apoptotic and anti-apoptotic members [45]. Bcl-2 proteins often form heterodimer complexes with Bax proteins, which result in the release of cytochrome c from the mitochondria and subsequent induction of cell death [46]. Hence, an increase in the ratio of Bax/Bcl-2 is considered as one of the major markers of pre-apoptosis. Several natural compounds that have been shown to influence the Bax/Bcl-2 ratio in cancer cells are (−)-epigallocatechin-3-gallate (EGCG) and resveratrol [47, 48]. In reference to this, results of our study also suggest that CT1 effectively induces apoptosis in MCF-7 cells through dysregulation of the Bax/Bcl-2 ratio, which in turn results in the cleavage of procaspase-9, -3, and -6 into active effector caspases.

Western blot analysis also showed that treatment of CT1 not only activates apoptosis effector proteins such as caspase-3 and caspase-6, which is evident through a decrease in procaspase-3 and procaspase-6 protein levels, but also activates caspase-8. This strongly suggests that signals favoring the induction of apoptosis do not solely originate from the mitochondrial pathway, but may also be augmented by the extrinsic death receptor pathway, specifically through Fas-mediated mechanisms [22]. This is further supported in past studies revolving caspase cascades indicating that activated caspase-6 can directly process the transient activation of caspase-8 through an amplification loop to enhance apoptotic signals [49]. In agreement with this, we observed an initial reduction in procaspase-8 levels at 6 h, followed by a subsequent increase over the next 12 h.

5. Conclusion

For the first time, the biological activity of the active phytocompound, 7α-hydroxy-β-sitosterol (CT1) isolated from Chisocheton tomentosus, was characterized in various cancer cell lines. This compound was found to significantly inhibit the proliferation of MCF-7 human breast cancer cells among other cancer cell lines through dysregulation of Bax/Bcl-2 ratio and the induction of G0/G1 cell cycle arrest via inactivation of ERK1/2. Despite preliminary evidences describing the involvement of both caspase-mediated intrinsic and extrinsic pathways, further elucidation on other apoptotic targets coupled with in vivo studies are required for further development of this phytosterol oxide.


This study was supported by the University of Malaya Postgraduate Research Grant (PPP) (PS8198-2008A), (PV058/2011B), (PS239-2009C) and the University of Malaya Research Grant (UMRG) (RG037-10BIO).


  1. D. J. Mabberly and C. M. Pannell, Meliaceae in Tree Flora of Malaya, vol. 4, Forest Research Institute Malaysia, Kuala Lumpur, Malaysia, 1989.
  2. K. Awang, C. S. Lim, K. Mohamad et al., “Erythrocarpines A-E, new cytotoxic limonoids from Chisocheton erythrocarpus,” Bioorganic & Medicinal Chemistry, vol. 15, no. 17, pp. 5997–6002, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. I. A. Najmuldeen, A. H. A. Hadi, K. Awang et al., “Chisomicines A-C, limonoids from Chisocheton ceramicus,” Journal of Natural Products, vol. 74, no. 5, pp. 1313–1317, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Mohamad, Y. Hirasawa, M. Litaudon et al., “Ceramicines B-D, new antiplasmodial limonoids from Chisocheton ceramicus,” Bioorganic & Medicinal Chemistry, vol. 17, no. 2, pp. 727–730, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. N. Joshi, B. L. Chowdhury, S. P. Vishnoi, A. Shoeb, and R. S. Kapil, “Antiviral activityof (+)-odorinol1,” Planta Medica, vol. 53, pp. 254–255, 1987. View at Publisher · View at Google Scholar
  6. J. M. Agbedahunsi, F. A. Fakoya, and S. A. Adesanya, “Studies on the anti-inflammatory and toxic effects of the stem bark of Khaya ivorensis (Meliaceae) on rats,” Phytomedicine, vol. 11, no. 6, pp. 504–508, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Oliver-Bever, Medicinal Plants in Tropical West Africa, Cambridge University Press, Cambridge, UK, 1986.
  8. S. Omar, J. Zhang, S. MacKinnon et al., “Traditionally-used antimalarials from the Meliaceae,” Current Topics in Medicinal Chemistry, vol. 3, no. 2, pp. 133–139, 2003. View at Google Scholar · View at Scopus
  9. N. H. Nagoor, N. Shah Jehan Muttiah, C. S. Lim, L. L. A. In, K. Mohammad, and K. Awang, “Regulation of apoptotic effects by erythrocarpine E, a cytotoxic limonoid from Chisocheton erythrocarpus in HSC-4 human oral cancer cells,” PLoS One, vol. 6, no. 8, Article ID e23661, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Rubis, A. Paszel, M. Kaczmarek, M. Rudzinska, H. Jelen, and M. Rybczynska, “Beneficial or harmful influence of phytosterols on human cells?” British Journal of Nutrition, vol. 100, no. 6, pp. 1183–1191, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Paniagua-Pérez, E. Madrigal-Bujaidar, S. Reyes-Cadena et al., “Cell protection induced by beta-sitosterol: inhibition of genotoxic damage, stimulation of lymphocyte production, and determination of its antioxidant capacity,” Archives of Toxicology, vol. 82, no. 9, pp. 615–622, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. H. Ju, L. M. Clausen, K. F. Allred, A. L. Almada, and W. G. Helferich, “β-sitosterol, β-sitosterol glucoside, and a mixture of β-sitosterol and β-sitosterol glucoside modulate the growth of estrogen-responsive breast cancer cells in vitro and in ovariectomized athymic mice,” Journal of Nutrition, vol. 134, no. 5, pp. 1145–1151, 2004. View at Google Scholar · View at Scopus
  13. S. Kurban, F. Erkoç, and S Erkoç, “Quantum chemical treatment of β-sitosterol molecule,” Pharmaceutical Biology, vol. 48, no. 6, pp. 637–642, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. T. A. Woyengo, V. R. Ramprasath, and P. J. H. Jones, “Anticancer effects of phytosterols,” European Journal of Clinical Nutrition, vol. 63, no. 7, pp. 813–820, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Sudhamalla, M. Gokara, N. Ahalawat, D. G. Amooru, and R. Subramanyam, “Molecular dynamics simulation and binding studies of β-sitosterol with human serum albumin and its biological relevance,” Journal of Physical Chemistry B, vol. 114, no. 27, pp. 9054–9062, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Ryan, J. Chopra, F. McCarthy, A. R. Maguire, and N. M. O'Brien, “Qualitative and quantitative comparison of the cytotoxic and apoptotic potential of phytosterol oxidation products with their corresponding cholesterol oxidation products,” British Journal of Nutrition, vol. 94, no. 3, pp. 443–451, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Hovenkamp, I. Demonty, J. Plat, D. Lütjohann, R. P. Mensink, and E. A. Trautwein, “Biological effects of oxidized phytosterols: a review of the current knowledge,” Progress in Lipid Research, vol. 47, no. 1, pp. 37–49, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Otaegui-Arrazola, M. Menéndez-Carreño, D. Ansorena, and I. Astiasarán, “Oxysterols: a world to explore,” Food and Chemical Toxicology, vol. 48, no. 12, pp. 3289–3303, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. P. G. Bradford and A. B. Awad, “Phytosterols as anticancer compounds,” Molecular Nutrition & Food Research, vol. 51, no. 2, pp. 161–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. P. G. Bradford and A. B. Awad, “Modulation of signal transduction in cancer cells by phytosterols,” BioFactors, vol. 36, no. 4, pp. 241–247, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Rubis, A. Polrolniczak, H. Knula, O. Potapinska, M. Kaczmarek, and M. Rybczynska, “Phytosterols in physiological concentrations target multidrug resistant cancer cells,” Medicinal Chemistry, vol. 6, no. 4, pp. 184–190, 2010. View at Google Scholar · View at Scopus
  22. A. B. Awad, M. Chinnam, C. S. Fink, and P. G. Bradford, “β-Sitosterol activates Fas signaling in human breast cancer cells,” Phytomedicine, vol. 14, no. 11, pp. 747–754, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. D. O. Moon, K. J. Lee, Y. H. Choi, and G. Y. Kim, “β-Sitosterol-induced-apoptosis is mediated by the activation of ERK and the downregulation of Akt in MCA-102 murine fibrosarcoma cells,” International Immunopharmacology, vol. 7, no. 8, pp. 1044–1053, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. D. O. Moon, M. O. Kim, Y. H. Choi, and G. Y. Kim, “β-Sitosterol induces G2/M arrest, endoreduplication, and apoptosis through the Bcl-2 and PI3K/Akt signaling pathways,” Cancer Letters, vol. 264, no. 2, pp. 181–191, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Park, D. O. Moon, C. H. Rhu et al., “β-Sitosterol induces anti-proliferation and apoptosis in human leukemic U937 cells through activation of caspase-3 and induction of Bax/Bcl-2 ratio,” Biological & Pharmaceutical Bulletin, vol. 30, no. 7, pp. 1317–1323, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Park, D. O. Moon, C. H. Ryu et al., “β-Sitosterol sensitizes MDA-MB-231 cells to TRAIL-induced apoptosis,” Acta Pharmacologica Sinica, vol. 29, no. 3, pp. 341–348, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. C. O'Callaghan, D. A. Foley, N. M. O'Connell, F. O. Mccarthy, A. R. Maguire, and N. M. O'Brien, “Cytotoxic and apoptotic effects of the oxidized derivatives of stigmasterol in the u937 human monocytic cell line,” Journal of Agricultural and Food Chemistry, vol. 58, no. 19, pp. 10793–10798, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Roussi, A. Winter, F. Gosse et al., “Different apoptotic mechanisms are involved in the antiproliferative effects of 7β-hydroxysitosterol and 7β-hydroxycholesterol in human colon cancer cells,” Cell Death and Differentiation, vol. 12, no. 2, pp. 128–135, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Roussi, F. Gossé, D. Aoudé-Werner et al., “Perturbation of polyamine metabolism and its relation to cell death in human colon cancer cells treated by 7β-hydroxycholesterol and 7β-hydroxysitosterol,” International Journal of Oncology, vol. 29, no. 6, pp. 1549–1554, 2006. View at Google Scholar · View at Scopus
  30. S. Roussi, F. Gossé, D. Aoudé-Werner et al., “Mitochondrial perturbation, oxidative stress and lysosomal destabilization are involved in 7β-hydroxysitosterol and 7β-hydroxycholesterol triggered apoptosis in human colon cancer cells,” Apoptosis, vol. 12, no. 1, pp. 87–96, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. I. A. Najmuldeen, A. H. A. Hadi, K. Mohamad et al., “Steroids from Chisocheton tomentosus,” Malaysian Journal of Science, vol. 30, no. 2, pp. 144–153, 2011. View at Google Scholar · View at Scopus
  32. T. Gebäck, M. M. P. Schulz, P. Koumoutsakos, and M. Detmar, “TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays,” BioTechniques, vol. 46, no. 4, pp. 265–274, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. I. A. Najmuldeen, A. H. A. Hadi, K. Awang, K. Mohamad, and S. W. Ng, “17-(5-Ethyl-6-methyl-heptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13, 14,15,16,17-tetra-deca-hydro-1H-cyclo-penta[a]phenanthrene-3,7-diol from Chisocheton tomentosus (Meliaceae),” Acta Crystallographica Section E, vol. 64, no. 11, p. o2163, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Guerriero, M. D'Ambrosio, F. Pietra, C. Debitus, and O. Ribes, “Pteridines, sterols, and indole derivatives from the lithistid sponge Corallistes undulatus of the coral sea,” Journal of Natural Products, vol. 56, no. 11, pp. 1962–1970, 1993. View at Google Scholar · View at Scopus
  35. E. J. Cui, J. H. Park, H. J. Park et al., “Isolation of sterols from cowpea (Vigna sinensis) seeds and their promotion activity on HO-1,” Journal of Applied Biological Chemistry, vol. 54, no. 3, pp. 362–366, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Schroeder, M. Rohmer, J. P. Beck, and R. Anton, “7-Oxo-, 7α-hydroxy- and 7β-hydroxysterols from Euphorbia fischeriana,” Phytochemistry, vol. 19, no. 10, pp. 2213–2215, 1980. View at Google Scholar · View at Scopus
  37. N. Chaurasia and M. Wichtl, “Sterols and steryl glycosides from Urtica dioica,” Journal of Natural Products, vol. 50, no. 5, pp. 881–885, 1987. View at Google Scholar · View at Scopus
  38. D. J. Newman and G. M. Cragg, “Natural products as sources of new drugs over the 30 years from 1981 to 2010,” Journal of Natural Products, vol. 75, no. 3, pp. 311–335, 2012. View at Publisher · View at Google Scholar
  39. S. H. O'Shea, J. Schwarz, O. Kosyk et al., “In vitro screening for population variability in chemical toxicity,” Toxicological Sciences, vol. 119, no. 2, pp. 398–407, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Koschutnig, S. Heikkinen, S. Kemmo, A. M. Lampi, V. Piironen, and K. H. Wagner, “Cytotoxic and apoptotic effects of single and mixed oxides of β-sitosterol on HepG2-cells,” Toxicology in Vitro, vol. 23, no. 5, pp. 755–762, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Y. Misharin, A. R. Mehtiev, G. E. Morozevich, Y. V. Tkachev, and V. P. Timofeev, “Synthesis and cytotoxicity evaluation of 22,23-oxygenated stigmastane derivatives,” Bioorganic & Medicinal Chemistry, vol. 16, no. 3, pp. 1460–1473, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Yuste, A. Esparís-Ogando, E. Santos, and A. Pandiella, “Overexpression of RasN17 fails to neutralize endogenous ras in MCF7 breast cancer cells,” Journal of Biochemistry, vol. 137, no. 6, pp. 731–739, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Ley, K. Balmanno, K. Hadfield, C. Weston, and S. J. Cook, “Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim,” Journal of Biological Chemistry, vol. 278, no. 21, pp. 18811–18816, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. R. J. Fiddes, P. W. Janes, S. P. Sivertsen, R. L. Sutherland, E. A. Musgrove, and R. J. Daly, “Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells,” Oncogene, vol. 16, no. 21, pp. 2803–2813, 1998. View at Google Scholar · View at Scopus
  45. A. M. Petros, E. T. Olejniczak, and S. W. Fesik, “Structural biology of the Bcl-2 family of proteins,” Biochimica et Biophysica Acta, vol. 1644, no. 2-3, pp. 83–94, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. R. W. M. Hoetelmans, H. J. van Slooten, R. Keijzer, S. Erkeland, C. J. H. van de Velde, and J. H. van Dierendonck, “Bcl-2 and Bax proteins are present in interphase nuclei of mammalian cells,” Cell Death and Differentiation, vol. 7, no. 4, pp. 384–392, 2000. View at Google Scholar · View at Scopus
  47. V. P. Androutsopoulos, K. C. Ruparelia, A. Papakyriakou, H. Filippakis, A. M. Tsatsakis, and D. A. Spandidos, “Anticancer effects of the metabolic products of the resveratrol analogue, DMU-212: structural requirements for potency,” European Journal of Medicinal Chemistry, vol. 46, no. 6, pp. 2586–2595, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. D. Hsuuw and W. H. Chan, “Epigallocatechin gallate dose-dependently induces apoptosis or necrosis in human MCF-7 cells,” Annals of the New York Academy of Sciences, vol. 1095, pp. 428–440, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Inoue, G. Browne, G. Melino, and G. M. Cohen, “Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway,” Cell Death and Differentiation, vol. 16, no. 7, pp. 1053–1061, 2009. View at Publisher · View at Google Scholar · View at Scopus